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Epigenetic associations of type 2 diabetes
and BMI in an Arab population
Wadha A. Al Muftah1,2,3†, Mashael Al-Shafai1,2,3†, Shaza B. Zaghlool1†, Alessia Visconti4, Pei-Chien Tsai4,
Pankaj Kumar1, Tim Spector4, Jordana Bell4, Mario Falchi2,4 and Karsten Suhre1,4,5*
Abstract
Background: The prevalence of type 2 diabetes (T2D) and obesity has dramatically increased within a few generations,
reaching epidemic levels. In addition to genetic risk factors, epigenetic mechanisms triggered by changing environment
are investigated for their role in the pathogenesis of these complex diseases. Epigenome-wide association studies
(EWASs) have revealed significant associations of T2D, obesity, and BMI with DNA methylation. However, populations
from the Middle East, where T2D and obesity rates are highest worldwide, have not been investigated so far.
Methods: We performed the first EWAS in an Arab population with T2D and BMI and attempted to replicate 47 EWAS
associations previously reported in Caucasians. We used the Illumina Infinium HumanMethylation450 BeadChip to
quantify DNA methylation in whole blood DNA from 123 subjects of 15 multigenerational families from Qatar. To
investigate the effect of differing genetic background and environment on the epigenetic associations, we further
assessed the effect of replicated loci in 810 twins from UK.
Results: Our EWAS suggested a novel association between T2D and cg06721411 (DQX1; p value = 1.18 × 10−9). We
replicated in the Qatari population seven CpG associations with BMI (SOCS3, p value = 3.99 × 10−6; SREBF1,
p value = 4.33 × 10−5; SBNO2, p value = 5.87 × 10−5; CPT1A, p value = 7.99 × 10−5; PRR5L, p value = 1.85 × 10−4;
cg03078551, intergenic region on chromosome 17; p value = 1.00 × 10−3; LY6G6E, p value = 1.10 × 10−3) and one with
T2D (TXNIP, p value = 2.46 × 10−5). All the associations were further confirmed in the UK cohort for both BMI and T2D.
Meta-analysis increased the significance of the observed associations and revealed strong heterogeneity of the effect
sizes (apart from CPT1A), although associations at these loci showed concordant direction in the two populations.
Conclusions: Our study replicated eight known CpG associations with T2D or BMI in an Arab population.
Heterogeneity of the effects at all loci except CPT1A between the Qatari and UK studies suggests that the underlying
mechanisms might depend on genetic background and environmental pressure. Our EWAS results provide a basis for
comparison with other ethnicities.
Background
The Qatari population is one of the understudied Arab
populations in type 2 diabetes (T2D) and obesity research,
despite the high prevalence of these diseases among
Qataris, with an estimated prevalence of ~23 % for T2D
[44] and ~42 % for obesity (World Health Organization
2015) [58]. The increased prevalence of T2D and obesity
has occurred during a short period of time (2–3 genera-
tions), suggesting an important contribution to the disease
risk by changing environment and life style factors, whose
effects are potentially mediated by the epigenome. Epigen-
etic modifications are changes that do not alter the primary
DNA sequence itself and include DNA methylation, his-
tone modifications, and other changes in chromatin struc-
ture that may affect the regulation of gene expression [24,
39, 40]. These epigenetic modifications are thought to pro-
vide a link between environmental exposures and clinical
phenotypes and are also suspected to contribute to the un-
explained heritability of complex diseases [30].
The recent development of genome-wide DNA methy-
lation arrays, and of sequencing technologies, coupled
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with bisulfide treatment presents novel opportunities to
investigate the role of DNA methylation in complex dis-
eases through epigenome-wide association studies
(EWASs). Only a small number of EWASs have been
published so far on T2D [6, 7, 12, 14, 26, 52, 56] and on
obesity or BMI ([1, 2, 15, 16, 18]; Sun.D. et al. [49];
[57]). These studies identified new potential T2D- and
obesity-associated genes. Furthermore, efforts have been
made to study the effect of DNA methylation on gene
expression and on metabolic profiles in order to provide
better understanding of disease mechanisms [38, 40].
Most EWASs with T2D and obesity conducted so far
were focused on Caucasian populations, and little is
known about whether their findings translate to other
ethnicities and genetic backgrounds. We performed here
the first EWAS for T2D and BMI in an Arab population
using 123 individuals from 15 Qatari families.
Previous genetic studies have shown that translatability
between populations does not always hold. For example,
genetic variants at the PPARϒ locus that associate with
T2D in individuals of European descent seem not to
exert any effect on T2D risk in the Qatar population [5].
More discrepancies might be expected for epigenetic risk
factors, which are additionally under strong environmen-
tal influence. To address this question, we investigated
whether the effect of the replicated loci was homoge-
neous between Caucasians and the Qatari population by
using data from 810 twins from UK, therefore having
different genetic backgrounds and under different life
style/environmental pressures.
Methods
The studies were conducted in concordance with the
Helsinki Declaration of ethical principles for medical
research involving human subjects. The studies were
approved by the relevant institutional review boards
in Qatar (Institutional Review Board of Weill Cornell
Medical College in Qatar, ethical approval numbers
2012–003 and 2012–0025) and in the UK (Guy’s and
St. Thomas’ Hospital Ethics Committee). Written in-
formed consent was obtained from every participant
in each study.
Qatari family study
The methylation data used in this study was obtained
from whole blood (the only easily accessible type of sam-
ple) and has been previously described in [59]. Details
on whole-genome sequencing can be found in [27].
Briefly, the study group consisted of 123 subjects of
Qatari descent from 15 families of various sizes and
structures. The dataset included 72 females with mean
age 39 (±16.9) years and 51 males with mean age 36.3
(±17.2) years. The average BMI of the females was 28.3
(±6.2) kg/m2 and of the males was 29.2 (±7.2) kg/m2. A
total of 30 individuals consisting of 19 females and 11
males were previously diagnosed with T2D, ascertained
by the diabetes clinic at Hamad Medical Corporation.
T2D subjects were receiving treatment for diabetes, and
no other major diseases were reported. DNA methyla-
tion profiling was performed by Illumina using the Infi-
nium HumanMethylation450K BeadChip platform and
reported in the form of beta values. After quality control
and exclusion of individual probes containing SNPs
within a region of ±110 base pairs of the CpG site, based
on 40× whole-genome sequencing data [27], a total of
468,472 probes were selected for this study.
Normalization was carried out using the Lumi:QN
+BMIQ pipeline, using the smoothQuantileNormaliza-
tion method (Additional file 1: Figure S1). Blood cell
type coefficients of monocytes, granulocytes, NK-cells, B
cells, CD8+-T-cells, and CD4+-T-cells were estimated
from the methylation data using the method described
by Houseman et al. [22].
TwinsUK cohort
The TwinsUK cohort was established in 1992 to recruit
monozygotic and dizygotic twins [34]. More than 80 %
of participants are healthy female Caucasians (age range
from 16 to 98 years old). The cohort includes more than
13,000 twin participants from all regions across the
United Kingdom, and many have had multiple visits over
the years. The TwinsUK cohort has been used in many
epidemiological studies and is representative of the gen-
eral UK population for a wide range of diseases and
traits [3]. DNA methylation was measured for 877 indi-
viduals randomly selected from the TwinsUK cohort,
810 of who had both BMI and T2D information. All 810
subjects were female Caucasians. The average BMI was
27.8 (±5.2) kg/m2 and 32 individuals were previously di-
agnosed with T2D. The Infinium HumanMethylation450
BeadChip (Illumina Inc, San Diego, CA, USA) was used
to measure DNA methylation. Details of experimental
approaches have been previously described [54].
Normalization was carried out using the “minfi” R pack-
age [4], a procedure equivalent to the Lumi:QN+BMIQ
pipeline. DNA methylation probes that mapped incor-
rectly or to multiple locations in the reference sequence
and probes with detection p value of >0.05 or missing
values were removed, resulting in 452,874 probes. Blood
cell type coefficients were estimated from the methyla-
tion data using the method described by Houseman et
al. [22].
Statistical analysis
Associations of T2D and BMI with DNA methylation
levels in the Qatari family study and in the TwinsUK co-
hort were carried out within a variance component
framework to model the resemblance among family
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members. Specifically, the association between the
phenotypic traits and DNA methylation levels was evalu-
ated by using a linear mixed model where the total
phenotypic variance was partitioned into polygenic and
environmental variance, the latter including also meas-
urement errors. DNA methylation levels were modeled
as fixed effects, whilst the polygenic and environmental
effects were modeled as random components. The
phenotypic covariance matrix between subjects was
modeled using the matrix of the expected proportion of
alleles shared IBD over the genome between each pair of
individuals. The significance of the associations was eval-
uated by comparing the likelihood of a full model in-
cluding the methylation status in the fixed effect, and
the likelihood of a null model where the effect of DNA
methylation values was constrained to zero. Age, sex
(only for the Qatari dataset), smoking status, and the six
Houseman blood cell type coefficients (for B cells, gran-
ulocytes, monocytes, natural killer cells, CD8+-T-cells,
and CD4+-T-cells) were included in the association
model. Additionally, BMI association analysis included
T2D status as confounder and vice versa. BMI values
were standardized to have zero mean and one standard
deviation. Given the limited sample size, and to avoid
potential inflation of the association statistics by directly
carrying out the study on selected probes, we prelimin-
arily performed an EWAS in the Qatari family sample
using the whole set of probes. False discovery rate was
evaluated using Storey’s method [47].
Selection of CpG sites for replication
At the time this study was conducted, two large EWASs
for T2D [12, 26] and two for obesity and BMI [15, 16]
were available. We attempted to replicate the most sig-
nificant CpG probe for each reported locus that reached
genome-wide significance in at least one of these four
studies, resulting in eight CpG probes for T2D (Table 1)
and 39 for obesity and BMI (Table 2). Conservative Bon-
ferroni method was used to correct for multiple testing,
considering an association replicated with T2D if its p
value was lower than 6.25 × 10−3 (0.05/8) and with BMI
if its p value was lower than 1.28 × 10−3 (0.05/39).
Meta-analysis
Meta-analyses between the Qatari and UK samples were
carried out using the Genome-Wide Association Meta-
Analysis (GWAMA) software [29]. Specifically, we used
a fixed effects model with inverse variance to combine
the regression coefficients of each study and their stand-
ard errors. Inter-study heterogeneity was estimated by
using the Cochran’s Q test and by measuring the pro-
portion of variability that is explained by between-trial
heterogeneity (I2 estimates, [21]), both implemented in
GWAMA.
Results
Our EWAS (Additional file 2: Figure S2 and Add-
itional file 3: Figure S3) identified one CpG associ-
ation with T2D that reached genome-wide
Bonferroni significance (p value <1.07 × 10−7)
(cg06721411 at DQX1; p value = 1.18 × 10−9). No
methylation probes were significantly associated with
BMI after Bonferroni correction for multiple testing,
the strongest association being at cg17501210
(RPS6KA2; p value = 4.90 × 10−7). The full EWAS as-
sociation data is available as Additional files 4 and 5.
Q-Q plots (Additional file 3: Figure S3) of the
EWASs for BMI and T2D showed mild inflation of
the p value statistics (the genomic inflation factor
was 1.10 for T2D and 1.09 for BMI). We also repli-
cated the association of our top T2D CpG,
cg06721411 (DQX1), in the TwinsUK cohort (p
value = 9.00 × 10−3).
We calculated the heritability of DNA methylation at
these probes in the Qatari families. At 1 % FDR, 41,374
(about 10 %) methylation levels showed segregation be-
tween family members (median heritability = 0.70; first to
third quartile = 0.31–1.00). The replicated loci showed
Table 1 Replication of T2D-DNA methylation associations in the Qatari family study. The betas represent the slope of the regression
model indicating the rate of change in the dependent variable (trait) as independent variable (methylation beta value) changes.
Coordinates are in hg19
Probe Chr Position Gene symbol Beta SE p value Reference
cg19693031 1 145441552 TXNIP −2.41 0.57 2.46 × 10−5 [12, 26]
cg00574958 11 68607622 CPT1A −3.77 2.07 0.068 [12, 26]
cg11024682 17 17730094 SREBF1 1.99 1.30 0.124 [12]
cg09152259 2 128156114 PROC −1.02 0.71 0.148 [12]
cg06500161 21 43656587 ABCG1 2.17 1.52 0.153 [12]
cg04999691 7 150027050 C7orf29 1.87 1.40 0.182 [12]
cg02650017 17 47301614 PHOSPHO1 −3.22 2.58 0.212 [12]
cg18181703 17 76354621 SOCS3 −0.66 0.91 0.465 [12]
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heritability between 0.46 and 0.96, apart from cg11024682
(SREBF1) and cg07573872 (SBNO2), which were not sig-
nificant at 1 % FDR.
We replicated in the Qatari family study the associa-
tions between T2D and cg19693031 (TXNIP; p value =
2.46 × 10−5) (Table 1) and between BMI and cg18181703
Table 2 Replication of BMI-DNA methylation associations in the Qatari family study. The betas represent the slope of the regression
model indicating the rate of change in the dependent variable (trait) as independent variable (methylation beta value) changes.
Coordinates are in hg19
Probe Chr Position Gene symbol Beta SE p value Reference
cg18181703 17 76354621 SOCS3 −10.78 2.34 3.99 × 10−6 [12]
cg11024682 17 17730094 SREBF1 14.56 3.56 4.33 × 10−5 [15]
cg07573872 19 1126342 SBNO2 −9.96 2.48 5.87 × 10−5 [15]
cg00574958 11 68607622 CPT1A −21.04 5.33 7.99 × 10−5 [15]
cg07136133 11 36422377 PRR5L −10.43 2.79 1.85 × 10−4 [15]
cg03078551 17 41656298 NA −19.23 5.85 1.00 × 10−3 [15]
cg13123009 6 31681882 LY6G6E 12.41 3.80 1.10 × 10−3 [15]
cg09349128 22 50327986 NA −9.60 3.04 1.60 × 10−3 [15]
cg08972190 7 2138995 MAD1L1 11.11 3.54 1.70 × 10−3 [15]
cg06192883 15 52554171 MYO5C 6.68 2.27 3.20 × 10−3 [15]
cg06500161 21 43656587 ABCG1 11.90 4.17 4.30 × 10−3 [12]
cg27243685 21 43642366 ABCG1 11.01 4.11 7.30 × 10−3 [15]
cg06946797 16 11422409 NA −6.24 2.36 8.10 × 10−3 [15]
cg12992827 3 101901234 NA −5.60 2.14 8.90 × 10−3 [15]
cg23998749 1 154968781 NA 7.47 2.87 9.30 × 10−3 [15]
cg26354221 22 24822802 ADORA2A 12.11 4.77 0.011 [15]
cg11592786 15 89533581 NA −28.45 12.46 0.022 [15]
cg26403843 5 158634085 RNF145 3.63 1.61 0.024 [12]
cg26033520 10 74004071 NA 4.92 2.20 0.025 [15]
cg01844514 7 149557121 ZNF862 6.55 3.48 0.060 [15]
cg14017402 2 86225602 NA 3.98 2.35 0.090 [15]
cg22891070 19 46801642 HIF3A 1.64 1.05 0.120 [16]
cg08857797 17 40927699 VPS25 3.59 2.33 0.125 [15]
cg06876354 2 121020189 RALB 7.28 4.76 0.126 [15]
cg15871086 18 56526595 NA 4.08 2.86 0.155 [15]
cg07814318 15 31624584 KLF13 3.64 2.60 0.161 [16]
cg04816311 7 1066650 C7orf50 2.07 1.98 0.295 [15]
cg04927537 17 76976091 LGALS3BP 1.95 1.87 0.297 [15]
cg04869770 1 164561550 PBX1 2.46 2.50 0.325 [15]
cg25178683 17 76976267 LGALS3BP 2.23 2.38 0.350 [15]
cg20954977 2 232260116 B3GNT7 1.65 1.93 0.391 [15]
cg18568872 15 90606494 ZNF710 2.41 3.55 0.497 [15]
cg00863378 16 56549757 BBS2 1.37 2.51 0.584 [15]
cg17560136 8 21915510 EPB49 1.18 2.64 0.654 [15]
cg13708645 12 121974305 KDM2B 0.67 1.71 0.697 [15]
cg15695155 12 121973871 KDM2B 0.81 3.44 0.813 [15]
cg27614723 15 92399897 SLCO3A1 0.81 4.02 0.840 [15]
cg09664445 17 2612406 CLUH −0.86 5.28 0.871 [16]
cg18307303 5 158757456 IL12B −0.24 3.39 0.943 [15]
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(SOCS3; p value = 3.99 × 10−6), cg11024682 (SREBF1; p
value = 4.33 × 10−5), cg07573872 (SBNO2; p value =
5.87 × 10−5), cg00574958 (CPT1A; p value = 7.99 × 10−5),
cg07136133 (PRR5L; p value = 1.85 × 10−4), cg03078551
(intergenic region on chromosome 17; p value = 1.00 ×
10−3), and cg13123009 (LY6G6E; p value = 1.10 × 10−3)
(Table 2). Boxplots and scatter plots of these associations
are in Figs. 1 and 2. The distributions of the methylation
values for these eight CpG sites are in Additional file 6:
Figure S4. Although we decided to adopt Bonferroni cor-
rection for the replication study, 12 additional associa-
tions with BMI showed nominal level of significance and
the same direction of the associations as the original
EWASs (Table 2).
The eight replicated associations were analyzed in the
TwinsUK cohort, and effects were combined in meta-
analyses. The meta-analysis of BMI with the TwinsUK
results indicated a moderate presence of heterogeneity
between the two studies for cg00574958 (CPT1A; I2 =
56.8 %; Cochran’s heterogeneity statistic’s p value >0.05)
and increased the significance of this association to p
value = 7.32 × 10−14. On the other hand, a considerable
presence of heterogeneity between the two studies was
identified for all the other associations (Table 3;
Cochran’s heterogeneity statistic’s p value <0.05), despite
association at these loci was significant in both popula-
tions and with concordant direction (Table 3).
Discussion
The high prevalence of T2D and obesity in Qatar moti-
vated the initiation of genetic and epigenetic research in
this country. To the best of our knowledge, this is the
first association study of CpG methylation with T2D and
BMI in an Arab population. We conducted a full EWAS
and attempted to replicate in the Qatari population eight
CpG sites associated with T2D (Table 1) and 39 CpG
sites associated with BMI (Table 2) in Caucasians. Our
EWAS with T2D (Additional file 2: Figure S2 and Add-
itional file 3: Figure S3) identified one significantly asso-
ciated CpG site at cg06721411 (DQX1; p value = 1.18 ×
10−9), while the strongest association with BMI at
cg17501210 (RPS6KA2; p value = 4.90 × 10−7) did not
reach genome-wide significance. The inflation shown in
the Q-Q plots is possibly due to hidden confounders, in-
cluding potentially reduced folate levels in diabetic sub-
jects. However, the observed inflation is only moderate
and does not substantially affect our conclusions. As
only cg06721411 (DQX1) in the T2D EWAS achieved
Bonferroni significance criteria in our discovery cohort,
we also replicated this locus in the TwinsUK cohort (p
value = 9.00 × 10−3). The effect was in the same direc-
tion. DQX1 (DEAQ box RNA-dependent ATPase 1) is a
protein coding gene located on chromosome 2 and is
classified as a member of the DEAD/H family. The high-
est expression of the DQX1 is found in the muscle and
liver [25].
Using a conservative Bonferroni correction, we repli-
cated eight of the 47 associations: SOCS3, SREBF1,
SBNO2, CPT1A, PRR5L, an intergenic region on
chromosome 17, and LY6G6E with BMI; and TNXIP1
with T2D, while nominal significance was reached for a
further 12 loci associated with BMI (Table 2). Despite
association with methylation at SOCS3 being previously
reported for both T2D and BMI [12, 26], only the associ-
ation with BMI was replicated in our study. However,
the association between SOCS3 and T2D was not signifi-
cant in the study of Chambers and colleagues after ad-
justment for BMI, suggesting that the observed
association with T2D in their study may be driven by
differences in adiposity between their T2D cases and
controls.
Although the mechanisms linking DNA methylation of
SOCS3, SREBF1, SBNO2, CPT1A, PRR5L, and LY6G6E
to BMI, and of TXNIP to T2D are not fully established
yet, some of these genes have been already functionally
linked to metabolic phenotypes. The replicated methyla-
tion sites are within proximity of known genes suggest-
ing a regulatory role of the methylation. However,
because expression data is not available for this popula-
tion, we used data from prior studies to confirm the
functional relevance of methylation to phenotypes and
the expression of these genes. For instance, TXNIP is a
Fig. 1 Boxplot of methylation beta values at cg19693031 (TXNIP)
against diabetes state. The middle lines show the medians of the
data while the boxes show the 25th to 75th percentiles (Q1 and Q3).
The whiskers extend to include 99 % of the data above while circles
represent outliers. Beta value distributions at this probe in the
diabetics and healthy individuals showed a difference in the levels
of background methylation (Wilcoxon test p value = 2.10 × 10−3)
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pro-apoptotic beta-cell factor and encodes for a protein
that acts as a regulator of metabolism and an inhibitor
of the antioxidant thioredoxins. A recent study showed
that TXNIP is involved in glucose regulation by control-
ling insulin sensitivity in the periphery of the human
body, and its expression is elevated in the skeletal mus-
cles in T2D patients [37] indicating a linkage to pheno-
type. We observed concordant results in this study:
individuals diagnosed with T2D show lower levels of
TXNIP methylation, thus suggesting higher TXNIP
Fig. 2 Scatter plots of BMI against methylation beta values. Red lines represent the slopes of the regression model. BMI values were corrected for
age and sex
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expression. Also, SOCS3 belongs to the SOCS protein
family, which is rapidly induced by cytokines, and acts
as an inhibitor of various cytokine signaling pathways.
Previous studies have shown that SOCS3 is linked to
phenotype by being a negative regulator of leptin [9, 10]
and insulin signaling [17, 42, 45]. In addition, there is
evidence for association between variants located near
SOCS3 with glucose homeostasis, BMI, and other obes-
ity traits [50, 51]. It was also shown that expression of
SREBF1 was reduced in adipose and skeletal muscle of
diabetic subjects [12, 26]. SREBF1 was shown to regulate
carbohydrate metabolism and synthesis in an animal
model of obesity and T2D [43]. In another study, qPCR
experiments showed that CPT1A expression is corre-
lated with the methylation status of CPT1A gene with p
value = 4.1 × 10−14 and replicated in the Framingham
Heart Study with p value = 3.1 × 10−13 [23]. Differential
methylation at CPT1A was also found to influence gene
expression in Dick et al. ([15, 16]; Sun.D. et al. [49]).
Also, [55] showed an increase of the suppressor of the
cytokine signaling proteins including SOCS3 in the liver,
muscle, and fat, in obesity. SOCS3 overexpression in the
fat cells was accompanied by glycogen synthesis and ac-
tivation of glucose uptake. Finally, we also used a re-
cently available database [11] to understand whether our
T2D EWAS hit and the eight replicated were associated
with any gene expression level. We found that all methy-
lation sites had more than one association with expres-
sion (cis-meQTL, cis-eQTM, and/or trans-meQTL) at
5 % FDR. Therefore, differential methylation may sug-
gest a regulatory role.
Interestingly, two CpG sites replicated by our study
(CPT1A and TXNIP) and a third CpG we attempted to
replicate (ABCG1) were also the only probes significantly
associated with alpha-hydroxybutyrate (AHB) in our re-
cent EWAS with blood serum metabolomics traits
(cg00574958 in CPT1A, p value = 1.3 × 10−10; cg06500161
in ABCG1, p value = 7.8 × 10−6; cg19693031 in TXNIP, p
value = 7.2 × 10−8) [38]. AHB is a sub-product of the ke-
tones metabolism; elevated AHB levels indicate potential
insulin resistance [20], and this biomarker is part of the
metabolomics-based pre-diabetes test Quantose™[53].
Other biomarkers of T2D and pre-diabetes have
been previously associated with methylation at
ABCG1, TXNIP, and CPT1A, including 3-methyl-2-
oxovalerate [33], glycine [19], several lipid traits, in-
cluding phosphatidylcholines (PCs) [48], chylomicrons,
and their remnants, very-low-density lipoprotein
(VLDL) and IDL cholesterol particles [38]. They all
showed diabetes-related effect directions that are in
agreement with the effect directions observed in this
study. Most interestingly, the list of metabolic traits
associated with CpGs [38] also includes the product
of CPT1A itself, palmitoylcarnitine. Furthermore,
higher levels of cg00574958 (CPT1A) methylation
were also associated with higher levels of related
long-chain fatty acids in the EWAS reported by Peter-
sen et al., including palmitate (16:0), stearate (18:0),
and oleate (18:1n9) (see Supplementary Table 5 of
[38]). Higher levels of cg06500161 (ABCG1) methyla-
tion were also associated in a recent EWAS with
higher levels of chylomicrons and VLDL-cholesterol
(see Supplementary Table 5 of [38] and Table 4).
The direction of the associations for all metabolites
at these three loci is coherent with the association of
CPT1A and TXNIP being in one direction (lower
methylation values associated with T2D or obesity)
and that of ABCG1 in the opposite one (higher
methylation values being associated with obesity).
Taken together, these observations support the claim
that lower methylation of the CPT1A and TXNIP loci
and increased methylation of the ABCG1 locus associ-
ate with a well-defined diabetes-specific metabolic
phenotype, which is mirrored by the association of
Table 3 Meta-analyses of the replicated loci in the Qatari study with the TwinsUK results
Trait Probe (gene) Qatari cohort TwinsUK cohort Meta-analysis
Beta SE p value Beta SE p value Beta (95U/95 L) SE p value I2 (%)
T2D cg19693031 (TXNIP) −2.41 0.57 2.46 × 10−5 −0.34 0.12 6.74 × 10−3 −0.43 (−0.66/−0.20) 0.12 2.71 × 10-4 92.1
BMI cg18181703 (SOCS3) −10.78 2.34 3.99 × 10−6 −2.90 0.71 5.45 × 10−5 −3.56 (−4.90/−2.23) 0.68 1.59 × 10−7 90.4
cg11024682 (SREBF1) 14.56 3.56 4.33 × 10−5 5.86 0.91 2.12 × 10−10 6.39 (4.67/8.12) 0.88 4.28 × 10−13 82.2
cg07573872 (SBNO2) −9.96 2.48 5.87 × 10−5 −2.64 0.81 1.16 × 10−3 −3.35 (−4.85/−1.84) 0.77 1.41 × 10−5 87.3
cg00574958 (CPT1A) −21.04 5.33 7.99 × 10−5 −12.43 1.90 1.08 × 10−10 −13.40 (−16.91/−9.89) 1.79 7.32 × 10−14 56.8
cg07136133 (PRR5L) −10.43 2.79 1.85 × 10−4 −3.82 0.78 8.02 × 10−7 −4.36 (−5.84/−2.89) 0.75 6.43 × 10−9 80.4
cg03078551 (NA) −19.23 5.85 1.00 × 10−3 −7.35 1.43 3.36 × 10−7 −8.02 (−10.74/−5.30) 1.39 7.97 × 10−9 74.3
cg13123009 (LY6G6E) 12.41 3.80 1.10 × 10−3 3.06 1.06 3.81 × 10−3 3.74 (1.73/5.74) 1.02 2.56 × 10−4 82.2
The table reports the results we obtained using a fixed effects model with inverse variance to combine the regression coefficients of each study and their
standard errors. P values, effect sizes (beta), and their standard errors (SE) are reported for both studies and for the meta-analysis results. For the meta-analysis, we
also reported: upper/lower 95 % CI for beta (beta 95U/95L), and heterogeneity estimates (I2)
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the loci with the respective clinical phenotypes, obes-
ity, and diabetes.
Replicated associations identified in this study were
also confirmed in the TwinsUK cohort (Table 3). Meta-
analysis increased the significance of the associations,
but highlighted heterogeneity of the effect sizes for all
loci but CPT1A. Some heterogeneity of effects between
our results and what was reported in the original papers
might be expected, as they could be driven by potential
differences in the normalization pipeline of the array
data or by the correction of the methylation values using
different confounders. However, despite that there were
no differences in the normalization pipeline or in the
use of confounders between the Qatari family sample
and the TwinsUK cohort, we still observed significant ef-
fect heterogeneity. This heterogeneity may partly be ex-
plained by the different environmental pressures. While
the standardized BMI distribution was not different be-
tween the two samples (Kolmogorov–Smirnov p value
>0.05), the distribution of six out of eight methylation
values at the tested probes was different in either loca-
tion or shape (Kolmogorov–Smirnov p value <0.05; Add-
itional file 6: Figure S4).
There are some limitations to our present study that
we are aware of. First, the use of Illumina Infinium
HumanMethylation450K arrays targets only a subset of
methylation sites across the human genome. Array-
based technologies are sensitive to artifacts induced by
genetic variants (SNPs) within probe binding sites. This
problem is commonly addressed by excluding probes
that contain known SNPs, based on the annotations
given in the Illumina manifest. However, these annota-
tions are based on SNP tagging technologies and might
provide incomplete information, in particular, in less
studied non-Caucasian populations. One of the strengths
of our present study is the ability to fully remove such
potentially confounding genetic effects, based on the
availability of whole-genome sequencing data with deep
coverage.
Second, DNA methylation was measured using DNA
extracted from whole blood that was the only accessible
type of sample and may not be representative of more
disease-relevant tissues for the diseases under study,
such as pancreatic cells and adipose tissues. Studies of
methylation in obesity or T2D based on disease-relevant
tissues such as the skeletal muscle, adipose tissue, or
pancreatic islets are interesting but only exist for rela-
tively small studies [8, 13, 28, 31, 32, 35, 36, 41, 46].
Since DNA methylation can be strongly tissue
dependent and as our data was obtained from blood
samples, for consistency, we only selected methylation
probes for replication from EWAS studies that were also
performed in the blood. In addition, the blood consists
of various cell types (including B cells, granulocytes,
monocytes, natural killer cells, and T cells subset) that
may bias methylation estimates. Estimation of cell type
coefficients from the methylation data was performed
using a method described by [22], and correction for
these coefficients in the association model is common
practice and it is also applied here.
Table 4 CpG–metabotype associations at the three replicated loci. Only associations with metabotypes that were significant at P
value <1.3 × 10−5 (Bonferroni correction of testing multiple metabolic traits) are shown; effect size (beta′), P value of the linear
model, and number of samples (N) (data from Supplementary Table 5 of [38]; for details on this dataset, see there)
Metabolic trait cg06500161 (ABCG1) cg00574958 (CPT1A) cg19693031 (TXNIP)
Beta′ P value N Beta′ P value N Beta′ P value N
1-Oleoylglycerol (1-monoolein) 9.435 2.84 × 10−11 1676 −0.983 4.37 × 10−11 1676 −0.841 1.02 × 10−14 1674
Alpha-hydroxybutyrate (AHB) 1.834 7.80 × 10−6 1749 −0.926 1.30 × 10−10 1749 −0.574 7.24 × 10−8 1747
3-methyl-2-oxovalerate 0.771 1.31 × 10−5 1749 −0.605 4.50 × 10−5 1749 −0.472 6.81 × 10−13 1747
Glycine −0.531 2.91 × 10−6 1744 4.064 7.58 × 10−9 1744 0.656 4.91 × 10−6 1742
Palmitoylcarnitine 1.729 1.35 × 10−5 1737 −0.849 2.28 × 10−6 1737 −0.579 3.11 × 10−8 1735
PC aa C36:4 2.549 2.82 × 10−5 1781 −0.947 2.07 × 10−8 1781 −0.628 1.66 × 10−6 1779
PC aa C42:0 −0.883 3.91 × 10−8 1781 22.276 3.36 × 10−6 1781 6.181 1.11 × 10−13 1779
PC aa C42:1 −0.844 4.63 × 10−7 1781 12.688 4.18 × 10−5 1781 4.631 4.93 × 10−12 1779
PC ae C44:6 −0.918 8.52 × 10−12 1781 17.438 4.88 × 10−6 1781 5.075 5.48 × 10−13 1779
Chylo-A (nM) 594.7 8.44 × 10−14 1773 −1.000 1.35 × 10−13 1773 −0.996 1.11 × 10−21 1771
Chylo-B (nM) 29.53 7.09 × 10−6 1766 −1.000 3.24 × 10−12 1766 −0.988 8.30 × 10−18 1764
Chylo-Rem (nM) 416.1 1.34 × 10−11 1772 −1.000 2.38 × 10−12 1772 −0.991 5.40 × 10−15 1770
IDL (nM) 30.86 1.32 × 10−9 1773 −0.993 6.00 × 10−7 1773 −0.868 2.22 × 10−7 1771
VLDL-A (nM) 150.7 2.72 × 10−13 1773 −1.000 9.23 × 10−14 1773 −0.985 5.73 × 10−19 1771
VLDL-B (nM) 166.0 4.22 × 10−13 1773 −1.000 9.83 × 10−12 1773 −0.979 9.24 × 10−16 1771
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Conclusions
Given the early state of the epigenome-wide technologies,
the number of published EWASs on T2D and obesity so
far is small. However, the availability of the technology
along with the availability of novel computational tools is
expected to accelerate the increase in the number of stud-
ies conducted in this field. To the best of our knowledge,
this study is the first EWAS of T2D and obesity in an
Arab population. Our EWAS identified one new CpG as-
sociation with T2D at DQX1 that reached genome-wide
Bonferroni significance. We also replicated eight previ-
ously reported T2D and BMI associations, although they
were not genome-wide significant, confirming the rele-
vance of these CpG sites to these phenotypes.
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